NODAL inhibition promotes differentiation of pacemaker-like cardiomyocytes from human induced pluripotent stem cells

Directed cardiomyogenesis from human induced pluripotent stem cells (hiPSCs) has been greatly improved in the last decade but directed differentiation to pacemaking cardiomyocytes (CMs) remains incompletely understood. In this study, we demonstrated that inhibition of NODAL signaling by a specific N...

Full description

Bibliographic Details
Main Authors: Sergey Yechikov, Hillary K.J. Kao, Che-Wei Chang, Dalyir Pretto, Xiao-Dong Zhang, Yao-Hui Sun, Regan Smithers, Padmini Sirish, Jan A. Nolta, James W. Chan, Nipavan Chiamvimonvat, Deborah K. Lieu
Format: Article
Language:English
Published: Elsevier 2020-12-01
Series:Stem Cell Research
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S1873506120303445
id doaj-d95b00c1c3d8483ba668486b05a981b6
record_format Article
collection DOAJ
language English
format Article
sources DOAJ
author Sergey Yechikov
Hillary K.J. Kao
Che-Wei Chang
Dalyir Pretto
Xiao-Dong Zhang
Yao-Hui Sun
Regan Smithers
Padmini Sirish
Jan A. Nolta
James W. Chan
Nipavan Chiamvimonvat
Deborah K. Lieu
spellingShingle Sergey Yechikov
Hillary K.J. Kao
Che-Wei Chang
Dalyir Pretto
Xiao-Dong Zhang
Yao-Hui Sun
Regan Smithers
Padmini Sirish
Jan A. Nolta
James W. Chan
Nipavan Chiamvimonvat
Deborah K. Lieu
NODAL inhibition promotes differentiation of pacemaker-like cardiomyocytes from human induced pluripotent stem cells
Stem Cell Research
Cardiogenesis
Sinoatrial node
Pacemaker
Human induced pluripotent stem cells
Differentiation
author_facet Sergey Yechikov
Hillary K.J. Kao
Che-Wei Chang
Dalyir Pretto
Xiao-Dong Zhang
Yao-Hui Sun
Regan Smithers
Padmini Sirish
Jan A. Nolta
James W. Chan
Nipavan Chiamvimonvat
Deborah K. Lieu
author_sort Sergey Yechikov
title NODAL inhibition promotes differentiation of pacemaker-like cardiomyocytes from human induced pluripotent stem cells
title_short NODAL inhibition promotes differentiation of pacemaker-like cardiomyocytes from human induced pluripotent stem cells
title_full NODAL inhibition promotes differentiation of pacemaker-like cardiomyocytes from human induced pluripotent stem cells
title_fullStr NODAL inhibition promotes differentiation of pacemaker-like cardiomyocytes from human induced pluripotent stem cells
title_full_unstemmed NODAL inhibition promotes differentiation of pacemaker-like cardiomyocytes from human induced pluripotent stem cells
title_sort nodal inhibition promotes differentiation of pacemaker-like cardiomyocytes from human induced pluripotent stem cells
publisher Elsevier
series Stem Cell Research
issn 1873-5061
publishDate 2020-12-01
description Directed cardiomyogenesis from human induced pluripotent stem cells (hiPSCs) has been greatly improved in the last decade but directed differentiation to pacemaking cardiomyocytes (CMs) remains incompletely understood. In this study, we demonstrated that inhibition of NODAL signaling by a specific NODAL inhibitor (SB431542) in the cardiac mesoderm differentiation stage downregulated PITX2c, a transcription factor that is known to inhibit the formation of the sinoatrial node in the left atrium during cardiac development. The resulting hiPSC-CMs were smaller in cell size, expressed higher pro-pacemaking transcription factors, TBX3 and TBX18, and exhibited pacemaking-like electrophysiological characteristics compared to control hiPSC-CMs differentiated from established Wnt-based protocol. The pacemaker-like subtype increased up to 2.4-fold in hiPSC-CMs differentiated with the addition of SB431542 relative to the control. Hence, Nodal inhibition in the cardiac mesoderm stage promoted pacemaker-like CM differentiation from hiPSCs. Improving the yield of human pacemaker-like CMs is a critical first step in the development of functional human cell-based biopacemakers.
topic Cardiogenesis
Sinoatrial node
Pacemaker
Human induced pluripotent stem cells
Differentiation
url http://www.sciencedirect.com/science/article/pii/S1873506120303445
work_keys_str_mv AT sergeyyechikov nodalinhibitionpromotesdifferentiationofpacemakerlikecardiomyocytesfromhumaninducedpluripotentstemcells
AT hillarykjkao nodalinhibitionpromotesdifferentiationofpacemakerlikecardiomyocytesfromhumaninducedpluripotentstemcells
AT cheweichang nodalinhibitionpromotesdifferentiationofpacemakerlikecardiomyocytesfromhumaninducedpluripotentstemcells
AT dalyirpretto nodalinhibitionpromotesdifferentiationofpacemakerlikecardiomyocytesfromhumaninducedpluripotentstemcells
AT xiaodongzhang nodalinhibitionpromotesdifferentiationofpacemakerlikecardiomyocytesfromhumaninducedpluripotentstemcells
AT yaohuisun nodalinhibitionpromotesdifferentiationofpacemakerlikecardiomyocytesfromhumaninducedpluripotentstemcells
AT regansmithers nodalinhibitionpromotesdifferentiationofpacemakerlikecardiomyocytesfromhumaninducedpluripotentstemcells
AT padminisirish nodalinhibitionpromotesdifferentiationofpacemakerlikecardiomyocytesfromhumaninducedpluripotentstemcells
AT jananolta nodalinhibitionpromotesdifferentiationofpacemakerlikecardiomyocytesfromhumaninducedpluripotentstemcells
AT jameswchan nodalinhibitionpromotesdifferentiationofpacemakerlikecardiomyocytesfromhumaninducedpluripotentstemcells
AT nipavanchiamvimonvat nodalinhibitionpromotesdifferentiationofpacemakerlikecardiomyocytesfromhumaninducedpluripotentstemcells
AT deborahklieu nodalinhibitionpromotesdifferentiationofpacemakerlikecardiomyocytesfromhumaninducedpluripotentstemcells
_version_ 1724378033764171776
spelling doaj-d95b00c1c3d8483ba668486b05a981b62020-12-19T05:04:56ZengElsevierStem Cell Research1873-50612020-12-0149102043NODAL inhibition promotes differentiation of pacemaker-like cardiomyocytes from human induced pluripotent stem cellsSergey Yechikov0Hillary K.J. Kao1Che-Wei Chang2Dalyir Pretto3Xiao-Dong Zhang4Yao-Hui Sun5Regan Smithers6Padmini Sirish7Jan A. Nolta8James W. Chan9Nipavan Chiamvimonvat10Deborah K. Lieu11Department of Internal Medicine, Division of Cardiovascular Medicine, University of California, Davis, Davis, CA 95817, USA; Institute for Regenerative Cures, University of California, Davis, Sacramento, CA 95817, USADepartment of Internal Medicine, Division of Cardiovascular Medicine, University of California, Davis, Davis, CA 95817, USA; Institute for Regenerative Cures, University of California, Davis, Sacramento, CA 95817, USADepartment of Pathology and Laboratory Medicine, University of California, Davis, Sacramento, CA 95817, USADepartment of Internal Medicine, Division of Cardiovascular Medicine, University of California, Davis, Davis, CA 95817, USA; Institute for Regenerative Cures, University of California, Davis, Sacramento, CA 95817, USADepartment of Internal Medicine, Division of Cardiovascular Medicine, University of California, Davis, Davis, CA 95817, USADepartment of Internal Medicine, Division of Cardiovascular Medicine, University of California, Davis, Davis, CA 95817, USA; Institute for Regenerative Cures, University of California, Davis, Sacramento, CA 95817, USADepartment of Internal Medicine, Division of Cardiovascular Medicine, University of California, Davis, Davis, CA 95817, USA; Institute for Regenerative Cures, University of California, Davis, Sacramento, CA 95817, USA; Bridges to Stem Cell Research Program, California State University Sacramento, Sacramento, CA 95819, USADepartment of Internal Medicine, Division of Cardiovascular Medicine, University of California, Davis, Davis, CA 95817, USA; Department of Veterans Affairs, Northern California Health Care System, Mather, CA 95655, USAInstitute for Regenerative Cures, University of California, Davis, Sacramento, CA 95817, USA; Department of Hematology and Oncology, University of California, Davis, Sacramento, CA 95817, USADepartment of Pathology and Laboratory Medicine, University of California, Davis, Sacramento, CA 95817, USADepartment of Internal Medicine, Division of Cardiovascular Medicine, University of California, Davis, Davis, CA 95817, USA; Department of Veterans Affairs, Northern California Health Care System, Mather, CA 95655, USADepartment of Internal Medicine, Division of Cardiovascular Medicine, University of California, Davis, Davis, CA 95817, USA; Institute for Regenerative Cures, University of California, Davis, Sacramento, CA 95817, USA; Corresponding author at: University of California, Davis, Department of Internal Medicine, Division of Cardiovascular Medicine, Institute for Regenerative Cures 1616, 2921 Stockton Blvd., Sacramento, CA 95817, USA.Directed cardiomyogenesis from human induced pluripotent stem cells (hiPSCs) has been greatly improved in the last decade but directed differentiation to pacemaking cardiomyocytes (CMs) remains incompletely understood. In this study, we demonstrated that inhibition of NODAL signaling by a specific NODAL inhibitor (SB431542) in the cardiac mesoderm differentiation stage downregulated PITX2c, a transcription factor that is known to inhibit the formation of the sinoatrial node in the left atrium during cardiac development. The resulting hiPSC-CMs were smaller in cell size, expressed higher pro-pacemaking transcription factors, TBX3 and TBX18, and exhibited pacemaking-like electrophysiological characteristics compared to control hiPSC-CMs differentiated from established Wnt-based protocol. The pacemaker-like subtype increased up to 2.4-fold in hiPSC-CMs differentiated with the addition of SB431542 relative to the control. Hence, Nodal inhibition in the cardiac mesoderm stage promoted pacemaker-like CM differentiation from hiPSCs. Improving the yield of human pacemaker-like CMs is a critical first step in the development of functional human cell-based biopacemakers.http://www.sciencedirect.com/science/article/pii/S1873506120303445CardiogenesisSinoatrial nodePacemakerHuman induced pluripotent stem cellsDifferentiation